Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Sonolysis during carotid endarterectomy: randomised controlled trial

D. Školoudík, T. Hrbáč, M. Kovář, V. Beneš, J. Fiedler, M. Branca, JB. Rossel, D. Netuka, SONOBIRDIE Trial Investigators

. 2025 ; 388 (-) : e082750. [pub] 20250319

Language English Country England, Great Britain

Document type Journal Article, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III

OBJECTIVE: To evaluate the effectiveness and safety of sonolysis using a low intensity 2 MHz pulsed wave ultrasound beam during carotid endarterectomy. DESIGN: Multicentre, phase 3, double blind, randomised controlled trial. SETTING: 16 European centres. PARTICIPANTS: 1004 patients (mean age 68 years; 312 (31%) female) were enrolled in the study between 20 August 2015 and 14 October 2020 until the interim analysis was performed. INTERVENTIONS: Sonolysis (n=507) versus sham procedure (n=497). MAIN OUTCOME MEASURES: The primary endpoint was the composite incidence of ischaemic stroke, transient ischaemic attack, and death within 30 days. The incidence of new ischaemic lesions on follow-up brain magnetic resonance imaging was the main substudy endpoint, and incidence of intracranial bleeding was the main safety endpoint. RESULTS: The results favoured the sonolysis group for the primary endpoint (11 (2.2%) v 38 (7.6%); risk difference -5.5%, 95% confidence interval (CI) -8.3% to -2.8%; P<0.001), as well as in the substudy for magnetic resonance imaging detected new ischaemic lesions (20/236 (8.5%) v 39/224 (17.4%); risk difference -8.9%, -15% to -2.8%; P=0.004). Sensitivity analysis resulted in a risk ratio for sonolysis of 0.25 (95% CI 0.11 to 0.56) for ischaemic stroke and 0.23 (0.07 to 0.73) for transient ischaemic attack within 30 days. Sonolysis was found to be safe, and 94.4% of patients in the sonolysis group were free from serious adverse events 30 days after the procedure. CONCLUSION: Sonolysis was safe for patients undergoing carotid endarterectomy and resulted in a significant reduction in the composite incidence of ischaemic stroke, transient ischaemic attack, and death within 30 days. TRIAL REGISTRATION: Clinicaltrials.gov NCT02398734.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009468
003      
CZ-PrNML
005      
20250429135440.0
007      
ta
008      
250415e20250319enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/bmj-2024-082750 $2 doi
035    __
$a (PubMed)40107675
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Školoudík, David $u Centre for Health Research, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic skoloudik@email.cz $1 https://orcid.org/0000000226513424 $7 xx0020614
245    10
$a Sonolysis during carotid endarterectomy: randomised controlled trial / $c D. Školoudík, T. Hrbáč, M. Kovář, V. Beneš, J. Fiedler, M. Branca, JB. Rossel, D. Netuka, SONOBIRDIE Trial Investigators
520    9_
$a OBJECTIVE: To evaluate the effectiveness and safety of sonolysis using a low intensity 2 MHz pulsed wave ultrasound beam during carotid endarterectomy. DESIGN: Multicentre, phase 3, double blind, randomised controlled trial. SETTING: 16 European centres. PARTICIPANTS: 1004 patients (mean age 68 years; 312 (31%) female) were enrolled in the study between 20 August 2015 and 14 October 2020 until the interim analysis was performed. INTERVENTIONS: Sonolysis (n=507) versus sham procedure (n=497). MAIN OUTCOME MEASURES: The primary endpoint was the composite incidence of ischaemic stroke, transient ischaemic attack, and death within 30 days. The incidence of new ischaemic lesions on follow-up brain magnetic resonance imaging was the main substudy endpoint, and incidence of intracranial bleeding was the main safety endpoint. RESULTS: The results favoured the sonolysis group for the primary endpoint (11 (2.2%) v 38 (7.6%); risk difference -5.5%, 95% confidence interval (CI) -8.3% to -2.8%; P<0.001), as well as in the substudy for magnetic resonance imaging detected new ischaemic lesions (20/236 (8.5%) v 39/224 (17.4%); risk difference -8.9%, -15% to -2.8%; P=0.004). Sensitivity analysis resulted in a risk ratio for sonolysis of 0.25 (95% CI 0.11 to 0.56) for ischaemic stroke and 0.23 (0.07 to 0.73) for transient ischaemic attack within 30 days. Sonolysis was found to be safe, and 94.4% of patients in the sonolysis group were free from serious adverse events 30 days after the procedure. CONCLUSION: Sonolysis was safe for patients undergoing carotid endarterectomy and resulted in a significant reduction in the composite incidence of ischaemic stroke, transient ischaemic attack, and death within 30 days. TRIAL REGISTRATION: Clinicaltrials.gov NCT02398734.
650    _2
$a lidé $7 D006801
650    12
$a karotická endarterektomie $x škodlivé účinky $x metody $7 D016894
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři $7 D000368
650    _2
$a dvojitá slepá metoda $7 D004311
650    12
$a tranzitorní ischemická ataka $x prevence a kontrola $x etiologie $7 D002546
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stenóza arteria carotis $x chirurgie $7 D016893
650    _2
$a ultrazvuková terapie $x metody $x škodlivé účinky $7 D014464
650    _2
$a ischemická cévní mozková příhoda $x prevence a kontrola $x epidemiologie $7 D000083242
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze III $7 D017428
700    1_
$a Hrbáč, Tomáš $u Centre for Health Research, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Department of Neurosurgery, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Kovář, Martin $u Department of Neurology, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Beneš, Vladimír $u Department of Neurosurgery, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $u Department of Neurosurgery, Regional Hospital Liberec, Liberec, Czech Republic
700    1_
$a Fiedler, Jiří $u Department of Neurosurgery, Medical Faculty, Masaryk University Brno, Brno, Czech Republic $u Department of Neurosurgery, České Budějovice Hospital, České Budějovice, Czech Republic
700    1_
$a Branca, Mattia $u CTU Bern, Department of Clinical Research, University of Bern, Bern, Switzerland
700    1_
$a Rossel, Jean-Benoit $u CTU Bern, Department of Clinical Research, University of Bern, Bern, Switzerland
700    1_
$a Netuka, David $u Department of Neurosurgery, Faculty Military Hospital Praha, Praha, Czech Republic
710    2_
$a SONOBIRDIE Trial Investigators
773    0_
$w MED00193492 $t BMJ $x 1756-1833 $g Roč. 388 (20250319), s. e082750
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40107675 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135436 $b ABA008
999    __
$a ok $b bmc $g 2311073 $s 1246549
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 388 $c - $d e082750 $e 20250319 $i 1756-1833 $m BMJ $n BMJ $x MED00193492
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...